Calcitonin Gene-Related Peptide CGRP Inhibitors Market Analysis 2025 – Insights for Long-Term Investment & Planning

The Business Research Company’s Calcitonin Gene-Related Peptide CGRP Inhibitors Global Market Report 2025 - Market Size, Trends, And Global Forecast 2025-2034

LONDON, GREATER LONDON, UNITED KINGDOM, June 16, 2025 /EINPresswire.com/ -- The Business Research Company’s Latest Report Explores Market Driver, Trends, Regional Insights - Market Sizing & Forecasts Through 2034

What Does The Data On The CGRP Inhibitors Market Size Indicate?
The calcitonin gene-related peptide CGRP inhibitors market size has shown significant growth in recent years. From $2.87 billion in 2024, it is anticipated to grow to $3.17 billion in 2025 at a compound annual growth rate CAGR of 10.6%. This growth during the historic period can partly be credited to increasing development investments, rising approval of new drugs, growing demand for non-opioid pain relievers, and an increased focus on personalized medicine.

Get Your Free Sample Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24182&type=smp

What Is The Anticipated Growth Of The CGRP Inhibitors Market?
The CGRP inhibitors market is poised for rapid growth in the upcoming years, predicted to reach $4.68 billion in 2029 at a CAGR of 10.2%. The acceleration in the forecast period can be attributed to the increasing prevalence of migraines, the growing adoption of preventive migraine treatments, rising patient awareness, and increasing healthcare expenditure. Trends to watch out for during the forecast period include the advancement of technology in drug formulation, the integration of digital health tools, developments in precision medicine, and improvements in biosimilars.

what's driving the demand for CGRP inhibitors forward?
A significant factor is the increasing prevalence of migraines. These intense headaches often cause throbbing pain, usually on one side of the head, coupled with nausea, vomiting, and light and sound sensitivity. With rising levels of stress acting as a trigger, the demand for effective treatments is clear. CGRP inhibitors offer a targeted, preventative mechanism compatible with both acute and chronic care regimens, reducing headache frequency and severity through efficient CGRP receptor blockade. This improves patient well-being and daily functioning. For instance, a January 2023 report by the National Library of Medicine noted that the global prevalence of migraines is between 14% and 15%, contributing to 4.9% of the global disease burden. The growing prevalence of migraines is undeniably driving market growth.

Order Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/calcitonin-gene-related-peptide-cgrp-inhibitors-global-market-report

Who Are The Keen Competitors In The CGRP Inhibitors Market?
Leading companies such as Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bristol Myers Squibb Company, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Amgen Inc., Otsuka Holdings Co. Ltd., Teva Pharmaceutical Industries Ltd., H. Lundbeck A/S, Kissei Pharmaceutical Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., Shin Nippon Biomedical Laboratories Ltd., Sosei Group Corporation, Nuvie Bio Inc., Vaxxinity Inc., Acherx LLC, AfaSci Inc. are making their presence known in the CGRP inhibitors market.

What Are The Emerging Trends In The CGRP Inhibitors Market?
A trend emerging in the market is the focus on developing innovative products aimed at getting approvals, such as CGRP receptor antagonists designed to enhance migraine treatment efficacy. They offer expanded therapeutic indications and more convenient administration routes, such as oral and intranasal formulations. For instance, AbbVie Inc. received FDA approval in April 2023 for QULIPTA atogepant to treat chronic migraines in adults, cementing the drug's place in the industry.

How Is The CGRP Inhibitors Market Segmented?
The CGRP inhibitors market as covered in the report is segmented by type of inhibitor, mechanism of action, route of administration, treatment, and end user. These include:

1 By Type Of Inhibitor: Monoclonal Antibodies, Small Molecules, Peptides
2 By Mechanism Of Action: Anti-Calcitonin Gene-Related Peptide CGRP Ligand, CGRP Receptor Antagonist
3 By Route of Administration: Oral, Nasal, Intravenous
4 By Treatment: Preventive Migraine Treatment, Acute Migraine Treatment
5 By End User: Hospitals, Specialty Clinics, Mail Order Pharmacies, Retail Pharmacies

What Regional Insights Impact The CGRP Inhibitors Market Logistics?
In terms of regional insights, North America was the largest region in the CGRP inhibitors market in 2024, with Asia-Pacific projected to be the fastest-growing region.

Browse Through More Similar Reports By The Business Research Company:

Protein Inhibitors Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/protein-inhibitor-global-market-report

Checkpoint Inhibitors Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/checkpoint-inhibitor-global-market-report

HER2 Inhibitors Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/her2-inhibitor-global-market-report

Get a glimpse of the market in a global perspective by the Business Research Company. With over 15000+ reports covering 27 industries and spanning 60+ geographies, the Business Research Company provides comprehensive, data-rich research and insights. Utilizing an array of 1,500,000 datasets, in-depth secondary research, and unique industry leader insights, you can stay ahead in the game.

Contact us at The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
info@tbrc.info
Visit us on social media:
LinkedIn
Facebook
X